Esta es la versión HTML de un fichero adjunto a una solicitud de acceso a la información 'Meetings with the pharmaceutical industry since March 1st 2020'.


From:
Cc:
SANTE CONSULT-B5; SANTE PHARMACEUTICALS B5
Subject:
FW: Chiesi Farmaceutici - request for a call
Date:
jeudi 5 novembre 2020 10:33:33
Attachments:
image001.png
image002.png
image003.png
image008.png
image009.jpg
image010.jpg
Dear 
 
Thank you very much for your email and for the opportunity to have a meeting with Chiesi
Farmaceutici.
 
Unfortunately, due to a very busy period for all colleagues and limited resources we will kindly
decline the invitation.
 
Nonetheless, we would like to stress that the sustainable development and use of
pharmaceuticals is one of the key areas of the future pharma strategy and we would be happy to
receive from you in writing any ideas or info you may have on this subject.
 
Kind regards,
 
Unit “Medicines: policy, authorisation and monitoring“
 
European Commission
DG Health and Food Safety
_____________
This message represents solely the views of its author and can not be regarded as the official
position of the Commission. It is intended solely for the person to whom it is addressed and may
contain confidential information. If you have received this message in error, please notify me as
soon as possible.
 
From: 
 
Sent: Friday, October 30, 2020 2:14 PM
To: SANTE CONSULT-B5 
Subject: Chiesi Farmaceutici - request for a call
 
 
Dear 
I am writing on behalf of Chiesi Farmaceutici to ask for the opportunity of a meeting with
you or your Unit.
 
Chiesi is a European research-focused healthcare group that researches, develops, and
markets innovative drugs in the respiratory therapeutics, specialist medicine and rare






disease areas. Chiesi shares authorities’ concerns related to the environmental impact of
Hydrofluorocarbon (HFC) propellants used in pressurized metered dose inhalers (pMDIs)
– hydrofluoroalkanes (HFA) 134a and 227ea.  Despite the very limited contribution of
HFAs for pharmaceutical use compared to the total F-gases, Chiesi is e committed to be
the first pharmaceutical company leading the way towards carbon minimal inhaler
solutions that preserve patient’s health and has recently shared its plans with EMA.
 
Officially registered as Benefit Corporation and being the largest global
pharmaceutical group to be awarded B Corp™ Certification, Chiesi strives to
minimise the environmental footprint of its products and has planned to become
carbon neutral by 2035. As the EU is shifting toward ambitious climate objectives
as set in the European Green Deal, Chiesi appreciate DG SANTE’s important role
in supporting the healthcare sector’s transition to greener pharmaceuticals and
practices. Chiesi would be grateful for the opportunity of a call with you in the next
days to share in more detail its plans and to discuss the sustainable development
and use of pharmaceuticals for the future.
 
We look forward to hearing from you soon.
With kind regards,
 
Senior Director
 
FTI Consulting
+
 
23 Avenue Marnix
1000 Brussels  Belgium
www.fticonsulting.com
EU Transparency Register: 29896393398-67
 
 
 
 
“2020 EMEA Public Affairs Consultancy of the Year - Holmes Report” 
Learn more about what’s happening in Brussels and in the EU on getready4.eu
 
 
 
 
Confidentiality Notice:
This email and any attachments may be confidential and protected by legal privilege. If you are not the
intended recipient, be aware that any disclosure, copying, distribution or use of the e-mail or any attachment is
prohibited. If you have received this email in error, please notify us immediately by replying to the sender and

then delete this copy and the reply from your system. Thank you for your cooperation. 
FTI Consulting Belgium SA. A member of FTI Consulting Inc. Registered at Avenue Marnix 23, 1000 Brussels,
Belgium. RCB. VAT BE 0478 948 485